Comtusi

Quick links to important sections

Comtusi

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Comtusi

What is Comtusi? Defining the Combination Expectorant and Antihistamine

Property Description
Active Ingredients Guaifenesin, Oxomemazine
Form Syrup, Oral solution
Pharmacological Class Expectorant and Sedative Antihistamine Combination
Common Use Symptomatic relief of cough and respiratory congestion
Origin Synthetic/Semi-synthetic

Comtusi is a fixed-dose combination medication intended for oral use, primarily classified as a dual-action respiratory agent. This preparation integrates an expectorant (Guaifenesin) with a sedative antihistamine (Oxomemazine). This specific combination, unlike single-ingredient treatments, is designed for the management of acute cough and congestion associated with various respiratory illnesses. This formulation is designed to combine two distinct modes of relief into a single preparation.


Comtusi’s Composition: Guaifenesin and Oxomemazine Components

The composition features two distinct active ingredients [INN]: Guaifenesin and Oxomemazine. Guaifenesin is classified as a mucoactive agent; its therapeutic purpose is to relieve chest congestion by thinning mucus in the air passages to facilitate coughing up phlegm. The second ingredient, Oxomemazine, acts as a potent H₁ receptor antagonist (H₁-antihistamine) and belongs to the phenothiazine derivatives group. This specific inclusion of Oxomemazine imparts the defining characteristic of this combination, distinguishing it from non-sedating multi-symptom cold products. The medicine is typically supplied as an oral solution or syrup, which utilizes an aqueous solution base for systemic absorption via the oral route of administration.


General Purpose: Relieving Congestion and Irritative Cough

The general therapeutic purpose of Comtusi is to manage acute symptoms by addressing two major sources of discomfort concurrently, such as a patient experiencing a wet, congested chest combined with an incessant, irritating cough. The Guaifenesin component helps to loosen and thin tenacious phlegm, thereby assisting the body in clearing the airways of chest congestion. Guaifenesin facilitates the discharge of secretions from the respiratory tract, providing relief from chest heaviness. Simultaneously, the Oxomemazine component utilizes its antihistaminic and central sedative agent properties to calm the irritation that stimulates the cough reflex. This combined mechanism ensures that both the physical impediment of thick secretions and the hyper-reactive coughing are managed, offering comfort during acute respiratory episodes.

What side effects are possible with Comtusi?

Possible Side Effects and Safety Information

The safety profile for Comtusi, a fixed-dose combination of Guaifenesin and Oxomemazine, is predominantly characterized by the properties of its sedative antihistamine component. Adverse reactions are officially categorized by frequency and the organ systems affected.

Frequency and System-Organ Classification

The most frequently documented adverse effects, classified as Common in regulatory documentation, are related to the Central Nervous System (CNS), including drowsiness and sedation. Uncommon effects include signs of anticholinergic action, such as dry mouth, constipation, and urinary retention, as well as psychiatric effects like confusion or hallucinations.

Officially recognized System-Organ Classes involved include Nervous System Disorders, Gastrointestinal Disorders, Psychiatric Disorders, and Skin and Subcutaneous Tissue Disorders.

Category Officially Documented Effects
Common Drowsiness, Sedation, Nausea, Vomiting
Uncommon Dry mouth, Constipation, Urinary retention, Confusion

Serious Reactions and Special Populations

Regulatory safety information notes the rare but serious potential for Hematological Disorders, including agranulocytosis and hemolytic anemia, linked to the phenothiazine structure of Oxomemazine. Use is formally restricted in individuals with a history of these blood disorders.

Specific safety considerations are defined for special populations. Older adults may exhibit increased susceptibility to CNS effects and heightened anticholinergic reactions. In the pediatric population, there is a documented risk of paradoxical excitation (e.g., agitation, restlessness). Regulatory texts mandate caution for patients with severe hepatic impairment due to the risk of increased drug exposure. The sedative effects are noted in official labels to be more pronounced at the beginning of treatment.

Overdose and Emergency Response

A significant overdose of Comtusi requires immediate medical attention due to the combined risks of its active components. Overdose manifestations may involve gastrointestinal distress, such as nausea and vomiting, alongside prominent central nervous system (CNS) effects. These CNS effects, driven primarily by the sedative antihistamine component, can range from severe drowsiness, confusion, and disorientation to serious outcomes including convulsion and coma.

The official regulatory profile highlights that excessive intake poses a serious cardiovascular risk, specifically severe hypotension and the potential for life-threatening heart rhythm disturbances, including a prolonged QT interval. Due to these risks, monitoring, including an initial and potentially repeated Electrocardiogram (ECG), is often required.

Immediate action is necessary for suspected overdose: seek immediate medical attention or contact a Poison Control Center right away, as officially mandated. Treatment is officially defined as symptomatic and supportive because no specific antidote is known. Regulatory documents also note that babies and children may be at increased risk for convulsions, while elderly patients are noted to be at risk for mental confusion or delirium.

Therapeutic Uses of Comtusi

What Comtusi Treats: Main Uses and Benefits

This medication is generally used to provide supportive relief during acute respiratory episodes, such as those associated with the common cold or flu. It is relevant when supportive symptom management is appropriate and contributes to addressing symptom clusters that may become intense or disruptive.

Comtusi is commonly used across conditions presenting with acute episodes that involve both a bothersome, irritating cough and chest congestion. Key indications include symptomatic assistance with acute cough, respiratory congestion, and symptoms related to minor throat or lung irritation when accompanied by mucus.

The core benefit is its use for managing these symptoms together in these scenarios. This combination is used to ease the overall symptom burden when congestion and an irritating cough occur together. This provides supportive relief when symptoms create noticeable interference with daily functioning.

Quick Fact: Relief for Dual Symptoms
Symptom focus: Used when patients experience thick phlegm along with a disruptive, irritative cough.
Primary benefit: Contributes to improved comfort by assisting in the management of tenacious secretions and reducing the intensity of coughing fits.

Regulatory References

  1. Guidance document: Non-prescription Oral Adult Cough, Cold and Flu Labelling Standard

Eligibility and Restrictions for Use

Official Eligibility Profile for Comtusi

The eligibility for Comtusi, a combination of Guaifenesin and a sedative antihistamine, is strictly defined by regulatory documents, particularly concerning the safety profile of the antihistamine component.

Eligibility Status Affected Population or Condition
CONTRAINDICATED (Must Not Use) Infants and children under 2 years of age.
Patients with known Hypersensitivity or a history of Agranulocytosis.
Patients with known risk of Narrow-Angle Glaucoma or Urinary Retention.
USE WITH CAUTION (Conditional Use) The Elderly (due to increased central nervous system sensitivity).
Patients with Severe Hepatic and/or Renal Impairment.

Age-Related Eligibility The medicine is absolutely prohibited for children under 2 years of age. Use is reserved for adults and adolescents, and permitted for children over 2 years of age, often based on body weight, as established in regulatory labeling.

Physiological Restrictions Use is Not Recommended for Pregnant Women (especially during the first trimester) and Breastfeeding Women because the effects on the fetus or infant are not sufficiently established by regulatory data. Special clinical monitoring is advised for patients with Epilepsy due to the drug's potential to lower the seizure threshold.

Connection to the overall eligibility profile Regulatory documents formally classify certain populations, such as infants under two and individuals with specific ophthalmic or prostatic conditions, as absolutely contraindicated. The official profile further places use under caution for sensitive groups like the elderly and those with organ impairment, establishing clear, label-based conditional criteria.

What should I know about interactions with other medicines?

The official interaction profile for Comtusi is established by its two active components, Oxomemazine and Guaifenesin, as detailed in government regulatory documents. The most stringent restriction is the prohibition of co-administration with non-Parkinson's Dopaminergics such as Cabergoline and Quinagolide, due to documented reciprocal antagonism.

The central nervous system (CNS) depressant properties of Oxomemazine lead to a high potential for pharmacodynamic potentiation when combined with other sedative agents, including Alcohol, hypnotics, neuroleptics, and certain antidepressants; co-use is discouraged. Additionally, Atropinic Drugs (such as certain phenothiazines and tricyclic antidepressants) may increase the risk of additive anticholinergic effects, which can include increased potential for urinary retention.

A key pharmacokinetic constraint involves substances that reduce intestinal absorption: Gastrointestinal agents, Antacids, and Charcoal must be separated from the product by more than two hours. Furthermore, Cough Suppressants (Antitussives) are not recommended due to a counter-therapeutic effect, as they may reduce Guaifenesin's expectorant efficacy. The product's profile also notes the risk of Oxomemazine accumulation in patients with severe hepatic and/or renal impairment and mentions that Guaifenesin may cause color interference with specific laboratory tests for urinary 5-HIAA and VMA.

Mechanism of Action

Comtusi is a humanized monoclonal antibody (IgG2) designed to target and neutralize the Receptor Activator of Nuclear Factor kappaB Ligand ( RANKL).

The drug is administered into the systemic circulation where it selectively binds to soluble and membrane-bound RANKL. This molecular interaction prevents RANKL from engaging with its cognate receptor, RANK, which is constitutively expressed on the surface of pre-osteoclasts and mature osteoclasts.

Inhibition of the RANK/ RANKL signaling axis suppresses the downstream cascade required for the differentiation, maturation, and survival of osteoclasts. The resulting decrease in the number and activity of these cells leads to a sustained reduction in osteoclast-mediated bone resorption. This physiological modulation alters the balance of bone remodeling, shifting the net activity toward the bone formation phase.

Dosage and Administration Information

Official Administration Guidelines for Comtusi

Comtusi is a fixed-dose combination medication strictly intended for oral administration as a solution or syrup. Proper usage involves precise dosage, timing, and population limits, ensuring the medicine is used for short-term symptomatic relief only.

Standard Dosing and Frequency

Doses must be measured accurately using a calibrated measuring device provided with the product; household spoons are not appropriate for measurement. For adults, the dosing schedule is intermittent, requiring a minimum interval of 4 hours between doses. The administration is restricted to a maximum of four doses per day, based on the limits of the combined sedative component.

Administration Context and Course Duration

To support the function of the expectorant, the medicine is typically taken with plenty of fluids (e.g., water). Due to the known sedative properties of Oxomemazine, it is often recommended that the final daily dose be administered in the evening (vesperal intake), especially at the initiation of use. Treatment is designed for short-term use, generally not exceeding seven days for acute symptom management.

Population-Specific Rules

Specific parameters apply to pediatric use. Dosage for children is calculated based on body weight (approximated as 1 mL of syrup per kilogram of body weight per day), and the medicine is explicitly contraindicated for administration to children under 2 years of age. If a dose is missed, it must be skipped if the next scheduled dose is imminent; double doses must never be taken to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Comtusi

Evidence for Use in Acute Cough and Respiratory Congestion (Combination)

Comtusi, as a fixed-dose combination, was studied in research exploring how symptoms change over time related to acute or disruptive episodes, such as those experienced during a common cold. The research primarily consists of short-term Randomized Controlled Trials (RCTs) conducted in populations of adults and adolescents with cough and congestion. The trials research examined patient-reported outcomes describing perceived discomfort and changes in overall symptom intensity over the short duration of the study period.

Systematic reviews contribute to the broader evidence landscape, though they often indicate that the evidence for fixed-dose cough and cold combinations is limited and heterogeneous. What remains uncertain for this specific combination is a recognized lack of robust, high-quality RCTs designed specifically to evaluate the measured outcomes when compared to a placebo. Research exploring long-term symptom changes is not well characterized.


Evidence Focusing on the Expectorant Component (Guaifenesin)

The Guaifenesin component was studied in research contexts involving conditions involving periods of heightened symptoms related to chest congestion. These studies research examined objective outcomes like measures of sputum thickness and viscosity, as well as patient-reported outcomes describing perceived discomfort related to phlegm. Studies data show patterns related to changes in the physical properties of respiratory secretions following administration, suggesting a possible association with changes in mucus properties. However, the findings were mixed when trying to link these changes directly to a consistent reduction in cough frequency.


What is Still Uncertain About the Research for Comtusi

Evidence highlights what is known—and what is still uncertain—about this medication. The certainty remains low for the efficacy of the specific fixed combination due to the scarcity of high-quality, low-risk-of-bias RCTs. Furthermore, the role of the sedative antihistamine component (Oxomemazine) in symptom patterns related to cough may require more modern, dedicated research, as highlighted by systematic reviews. The long-term effects are not fully established since the research focused exclusively on acute symptom management.

Key Studies & References Guidance document: Non-prescription Oral Adult Cough, Cold and Flu Labelling Standard

Frequently Asked Questions (FAQ)

Common questions about Comtusi (FAQ)

Q: Is Comtusi used to treat more than one condition?

Comtusi is officially indicated for the symptomatic relief of acute cough and respiratory congestion associated with respiratory illnesses. The formulation is defined as a dual-action agent, combining an expectorant (to help loosen mucus) with a sedative antihistamine (to address the cough reflex).

Q: Do the side effects of Comtusi usually go away over time?

Official labeling notes that the sedative effects of the medicine, such as drowsiness, may be more noticeable when treatment is first started. Beyond this specific observation, the documentation generally classifies adverse reactions by frequency (Common or Uncommon) rather than by duration.

Q: Is Comtusi known to interact with common pain relievers like ibuprofen?

The official product information lists specific drug classes that can interact with Comtusi, such as alcohol, hypnotics, and Dopaminergics. The official product information does not contain an explicit warning regarding interactions with non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen.

Q: Are there any specific foods or drinks that should be avoided while taking Comtusi?

Alcohol consumption is noted in regulatory information as being linked to a risk of increased sedative effects, and co-use is generally advised against. The official documents also recommend separating the administration of the medicine from certain gastrointestinal agents by more than two hours, but no specific solid foods are generally prohibited.

Q: Is Comtusi safe to use for people who are older?

Regulatory documents advise caution when Comtusi is used by older adults (the elderly). This is because regulatory guidance notes that older adults may exhibit increased susceptibility to its central nervous system and anticholinergic effects, such as dry mouth or urinary retention.

Q: Can children or teenagers take Comtusi?

Comtusi is absolutely contraindicated, meaning it must not be used, for children under two years of age. The medicine is permitted for use in children over two years of age, adolescents, and adults. Dosage for children over two is calculated based on body weight, according to official administration guidelines.

Q: Why is it necessary for a doctor to monitor certain things while taking Comtusi?

Official regulatory documents advise caution and clinical monitoring for patients with certain pre-existing conditions. These include patients with Epilepsy (as the drug has properties that may affect the seizure threshold) and those with severe hepatic (liver) and/or renal (kidney) impairment, due to the risk of drug accumulation in the body.

Q: Can Comtusi cause difficulty sleeping?

The drug is classified as a sedative antihistamine and commonly causes drowsiness and sedation. For certain populations, such as children, there is a documented risk of paradoxical excitation (e.g., agitation or restlessness), which is a reaction distinct from simple sedation.

Q: Is it normal to feel a little dizzy after taking Comtusi?

Regulatory documents list drowsiness and sedation as common effects. Due to the sedative component, patients are advised to exercise caution with activities requiring mental alertness.

Q: Are there any widely reported cases of allergic reactions to Comtusi?

A history of hypersensitivity (allergic reaction) to the drug's active ingredients or excipients is listed as a formal contraindication, which establishes a clear restriction on use. The safety profile also officially documents rare reactions involving the skin or blood.

Q: Is Comtusi considered a controlled substance?

Comtusi is officially classified as an expectorant and sedative antihistamine combination. The active ingredients, Oxomemazine and Guaifenesin, are generally not classified as controlled substances.

Q: Can I take vitamins or herbal supplements with Comtusi?

The official product information primarily details interactions with other prescription medications. It does not provide a general statement explicitly listing all possible vitamins or herbal supplements, and caution is advised when combining any substance with this medication.

Q: Are there any restrictions on driving or operating machinery while taking Comtusi?

Regulatory information advises caution regarding activities requiring mental alertness, such as driving or operating machinery. This warning is due to the drug’s known sedative effects, which can impair judgment and reaction time, especially when treatment begins.

Q: What kind of studies led to Comtusi's approval?

Regulatory approval data is primarily based on short-term Randomized Controlled Trials (RCTs). These studies were conducted in populations of adults and adolescents to examine how patient-reported symptom discomfort changed during acute episodes of cough and congestion.

Q: Can Comtusi interact with birth control pills?

The official interaction profile lists drug classes known to interact with Comtusi, such as CNS depressants, Dopaminergics, and Anticholinergics. However, there is no explicit statement in the labeling about interaction with oral hormonal contraceptives (birth control pills).

Q: How is the dosage of Comtusi typically adjusted?

The adult regimen follows a fixed, maximum-frequency schedule. For children over two years old, the dosage is calculated based on their body weight. Furthermore, the regulatory guidance advises special caution regarding use in patients with severe hepatic and/or renal impairment, which may influence a physician's dosing approach.

Q: What should be done if I suspect an interaction between Comtusi and another medicine?

Official patient information advises contacting a healthcare professional immediately if there is a suspicion of an adverse reaction or an interaction.

Q: Does Comtusi contain lactose or gluten?

The official product documentation, which includes the list of excipients (inactive ingredients), confirms whether common allergens like lactose or gluten are present in the final oral solution formulation.

Q: What does 'contraindicated' mean in the context of Comtusi?

The term 'contraindicated' means that the medication must not be used by certain patients or in the presence of specific conditions. For Comtusi, this includes infants under two years old and patients with conditions like narrow-angle glaucoma, as the term establishes a binding restriction against use for safety reasons.

Q: Are there any official documents that explain Comtusi's mechanism of action simply?

Yes, official patient information leaflets and regulatory sections describing the Pharmacodynamic Properties provide a simple explanation of how the drug works. They clarify that the expectorant component helps thin mucus and the antihistamine component helps to calm the cough reflex.

Q: Why might a doctor prefer prescribing Comtusi over another treatment option?

Comtusi is a fixed-dose combination that provides a dual mechanism of action in a single preparation. This simultaneous action—loosening mucus and calming the cough—is a known characteristic of its therapeutic strategy for symptomatic relief.

Q: Can Comtusi affect the immune system?

The drug's safety profile notes a rare but serious potential for Hematological Disorders, which are conditions affecting the blood. These include agranulocytosis, a severe drop in certain white blood cells essential for immune function, linked to the phenothiazine structure of the antihistamine component.

Q: Why is my doctor asking me about my full medical history before prescribing Comtusi?

The medicine is contraindicated in patients with specific conditions, such as narrow-angle glaucoma, urinary retention, and a history of agranulocytosis. A full medical history review is required to ensure that none of these official safety restrictions apply to the patient before the medication is prescribed.

How should Comtusi be stored and disposed of?

How to Store and Dispose of Comtusi

Comtusi (oral solution) must be stored at controlled room temperature, with a required range of 15 C to 30 C (59 F to 86 F). The product must be protected from environmental degradation; regulatory labeling explicitly states to avoid excessive heat and humidity and to protect from light.

Container Integrity and Safety

The container must be kept tightly closed to maintain product stability. Before use, the seal integrity must be verified, as the product must not be used if the security seal is broken or missing. A mandatory safety instruction on the label requires keeping the medication OUT OF REACH OF CHILDREN.

Disposal Requirements

Expired or unused Comtusi should be properly discarded. Regulatory guidance recommends asking a pharmacist for instructions on proper disposal and advises against disposing of the medicine in household trash or via wastewater, which ensures adherence to pharmaceutical waste guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Comtusi found in:

A-Z Index: